A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

• Diagnosis of Behçet Disease. At the time of diagnosis, subjects must meet the international study group criteria for Behçet Disease • Females of childbearing potential (FCBP) must have negative pregnancy tests and agree to use two forms of contraception throughout the study. • Males must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP • Laboratory criteria: Hgb ≥ 9 g/dL, WBC count ≥ 3000 /microL and ≤14,000/microL, platelet count ≥ 100,000 /microL,, serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L), total bilirubin ≤ 2.0 mg/dL, AST and ALT ≤ 1.5 X ULN • Two or more oral ulcers over the 28 day period before screening, with or without current treatment • Two or more oral ulcers at the time of randomization (Visit 2, Baseline)

• Pregnant or breast feeding • Any condition which places the subject at risk • Systemic fungal infection • History of TB infection within 3 years • History of recurrent bacterial infection • Mycobacterium TB as indicated by a positive PPD skin test • History of incompletely treated Mycobacterium tuberculosis • Clinically significant chest x-ray abnormality at screening. • Clinically significant ECG abnormality at screening • History of HIV infection • History of congenital or acquired immunodeficiency • Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening • Antibodies to Hepatitis C at screening • History of malignancy (except for treated basal-cell skin carcinomas > 3 years prior to screening) • Any active major organ involvement of Behçet Disease • Use of concomitant immune modulating therapy or topical corticosteroids. • Use of ocular corticosteroids • Use of any investigational medication within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer)